Targeting sphingosine-1-phosphate for cancer therapy.
This review summarises some important new findings that implicate sphingosine-1-phosphate (S1P) as a potent tumorigenic and angiogenic agent released from cancerous tumours into the tumour microenvironment. Also explored is the novel concept that bioactive lipid signalling molecules, like S1P, can themselves be targets for rational drug design, thereby opening up an entire class of lipidomic-based therapeutics for oncology and other human diseases.
Sabbadini
R A
RA
Department of Biology, San Diego State University, 5500 Campanile Dr, San Diego, CA 92182-4614, USA. rsabba@sunstroke.sdsu.edu
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D016209:Interleukin-8 / Q000378:metabolism; D008246:Lysophospholipids / Q000276:immunology* / Q000378:metabolism / Q000502:physiology; D051379:Mice; D008954:Models, Biological; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000276:immunology / Q000378:metabolism / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D000911:Antibodies, Monoclonal; D015850:Interleukin-6; D016209:Interleukin-8; D008246:Lysophospholipids; D042461:Vascular Endothelial Growth Factor A; C060506:sphingosine 1-phosphate; D013110:Sphingosine